614-864-4919 info@sermonixpharma.com
  • Facebook
  • Twitter
  • Linkedin
  • RSS
  • Facebook
  • Twitter
  • Linkedin
  • RSS
Sermonix Pharmaceuticals
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Pipeline
  • Lasofoxifene
  • For Patients
    • The ELAINE Study
    • The ELAINE 2 Study
  • News & Media
    • News
    • Media
  • Medical Meetings
  • Contact
Select Page

imageedit_3_6466720837

by Sermonix Pharmaceuticals | Jan 22, 2021

Recent Posts

  • Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023
  • Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
  • Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
  • Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
  • Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women’s Sexual Health Annual Meeting 2023

Recent Comments

    Archives

    • March 2023
    • February 2023
    • December 2022
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • December 2021
    • November 2021
    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    © Sermonix Pharmaceuticals